Logo

Underwriters Exercise Option on BG Medicine IPO

Feb 10, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BG Medicine said Wednesday that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG's common stock for $7 per share.

In total, BG sold 5.75 million shares at a price of $7 per share in the offering. The firm said in its prospectus for the offering that if the underwriters' over-allotment option was exercised in full, its net proceeds would be approximately $35.1 million.

BG went public late last week. Its shares closed at $8.19 in Wednesday trade on the Nasdaq.

Filed under

Diagnostics
Business News
BG Medicine
IPO
Breaking News
The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.